Last reviewed · How we verify

NCT06282380: FDA-AF

Fibricheck Detection cApabilities for Atrial Fibrillation

Completed NA Last updated 27 June 2024
What this trial tests

NA trial testing FibriCheck Mobile Application in Atrial Fibrillation in 330 participants. Completed in 26 June 2024.

Timeline
26 February 2024
Primary endpoint
26 June 2024
26 June 2024

Quick facts

Lead sponsorQompium NV
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment330
Start date26 February 2024
Primary completion26 June 2024
Estimated completion26 June 2024
Sites5 locations across Belgium, United States

Drugs / interventions tested

Conditions studied

Sponsor

Qompium NV

Who can join

22 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of accuracy of the FibriCheck Mobile Application on various smartphone devices, compared to the reference diagnosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Qompium NV trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06282380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing